Chimeric Antigen Receptor Cell Therapy

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Chimeric antigen receptor (CAR) cell therapy is an immuno-oncology (IO) approach. It has gained increasing momentum in the past few years, with two new CAR-T cell products approved in the US and EU in 2017 and 2018 respectively. Immuno-oncology therapies utilize the human body’s immune responses, both adaptive and innate, to target cancer. Most of the mechanisms involved in human IO therapies revolve around priming and boosting the immune system via stimulation of antigen-presenting cells, T-cells, or innate cells, reducing immunosuppression in the tumor environment by regulating inhibitory pathways, and enhancing adaptive or innate immunity.

The CAR cell therapy market research report provides quotes from eight US- and 5EU-based key opinion leaders, payers, and researchers. This report will help design development strategies by understanding innovative development strategies likely to improve CAR cell therapy perceptions and uptake in the future.

Approved CAR-T Cell Products

Some of the top approved CAR-T cell therapy products are Kymriah and Yescarta. Novartis has the advantage of its Kymriah being the first-to-market CAR cell therapy; however, physician and payer concerns regarding patient outcomes may negate this benefit and enhance Gilead’s Yescarta’s success. Although Yescarta was approved later than Kymriah, early data suggest efficacy may be greater, which Gilead could leverage to encourage use over Kymriah in overlapping indications.

Preclinical CAR Cell Products in Development in the 8MM by Sponsor Type

The key sponsor types for the preclinical CAR cell products in development in the 8MM are academic institution and company. Pharma and biotech companies are leading with most of the development.

CAR Cell Products in the 8MM Analysis, by Sponsor Type

CAR Cell Products in the 8MM Analysis, by Sponsor Type

For more insights into the sponsor types of CAR cell products in 8 MM, download a free report sample

CAR Cell Products in Development in the 8MM by Cell Type

The key cell types in the preclinical car cell products in development in the 8MM are T cells, NK cells, and cytokine-induced killer (CIK) cells. Most preclinical candidates are CAR T-cells, followed by NK cells.

CAR Cell Products in the 8MM Analysis, by Cell Type

CAR Cell Products in the 8MM Analysis, by Cell Type

For more insights into the cell types of CAR cell products in 8MM, download a free report sample

CAR Cell Therapy Market Challenges

The key challenges in the CAR cell therapy market are pricing issues, toxicity, manufacturing, and resistance.

Pricing issues: Pricing is an important potential barrier to accessing CAR cell therapies. Autologous CAR-T cell therapies are a high-cost therapy associated with expensive R&D, manufacturing, and administration procedures, so to be commercially viable for developers, they are likely to continue to be associated with high market prices.

CAR-T Cell Therapies Developed by 6MM Companies

Some of the leading companies in the CAR-T cell therapy development based in the 6MM are Novartis AG, Gilead Sciences, Inc., bluebird bio, Inc., The Bristol-Myers Squibb Company, Autolus, and Celyad Oncology among others.

CAR Cell Therapy Market Report Overview

Key Approved Products Kymriah and Yescarta
Key Sponsor Type Academic Institution and Company
Key Cell Type T cells, NK cells, and Cytokine-induced Killer (CIK) Cells
Leading Companies in 6MM Novartis AG, Gilead Sciences, Inc., bluebird bio, Inc., The Bristol-Myers Squibb Company, Autolus, and Celyad Oncology

Scope

GlobalData’s Chimeric Antigen Receptor Cell Therapy report combines primary research from a cross-specialty panel of oncology experts with in-house analyst expertise to provide an assessment of the development landscape (including regulation), key challenges, and future directions for CAR cell therapies.

Components of the slide deck include primary and secondary research:

  • Quotes from eight US- and 5EU-based key opinion leaders, payers, and researchers
  • Quotes from three Japan-based key opinion leaders
  • Summary of CAR-cell therapy mechanism of action and history of development
  • Overview of late-stage CAR cell pipeline and two marketed products
  • Outline of regulatory pathways in place for CAR cell therapies across the 8MM, challenges that currently face CAR cell therapies, and future directions for CAR cell therapies
  • Call-outs of key information and details
  • Insight from GlobalData’s specialist oncology analysts

Reasons to Buy

  • Develop business strategies by understanding the challenges facing CAR cell therapies.
  • Design development strategies by understanding innovative development strategies likely to improve CAR cell therapy perceptions and uptake in the future.
  • Be acquainted with regulatory processes relevant to CAR cell therapies across the US, 5EU, Japan, and China.
  • Develop strategies by understanding expert perceptions of currently approved CAR cell therapies, challenges facing CAR cell therapies, and future directions of CAR cell therapy.

Amgen Inc
Autolus Therapeutics Plc
Beijing Immunochina Medical Science & Technology Co Ltd
Bellicum Pharmaceuticals Inc
Bristol-Myers Squibb Co
bluebird bio Inc
CARsgen Therapeutics Ltd
Celgene Corp
Cell Medica Ltd
Cellular Biomedicine Group Inc
Celularity Inc
Celyad SA
Daiichi Sankyo Co Ltd
Fosun Pharmaceutical AG
Gilead Sciences Inc
Guangzhou Anjie Biomedical Technology Co Ltd
Hangzhou Converd Co Ltd
Hebei Senlang Biotechnology Inc Ltd
HRAIN Biotechnology Co Ltd
Juno Therapeutics Inc
Kite Pharma Inc
Nanjing Legend Biotech Co Ltd
NantKwest Inc
Nkarta Inc
Novartis AG
Ono Pharmaceutical Co Ltd
Shanghai GeneChem Co Ltd
Shanghai Sinobioway Sunterra Biotechnology Co Ltd
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
Sorrento Therapeutics Inc
Takara Bio Inc

Table of Contents

1 Table of Contents (PowerPoint Deck)

1. Preface

1.1 Related Reports

1.2 Upcoming Reports

1.3 Abbreviations

2. Executive Summary

3. Introduction

3.1 Chimeric Antigen Receptor Cell Therapy Mechanism of Action

3.2 History of Development of CAR Cell Products

3.3 Approved CAR-T Cell Products

3.4 Late-stage Pipeline CAR-T Cell Therapies

3.5 Preclinical Development of CAR Cell Products

4. Regulatory Pathways for CAR Cell Therapy

4.1 CAR Cell Therapy Regulation Overview in the 8MM

4.2 US CAR Cell Therapy Regulation

4.3 EU CAR Cell Therapy Regulation

4.4 Japan CAR Cell Therapy Regulation

4.5 China CAR Cell Therapy Regulation

5. Challenges for CAR Cell Therapy

5.1 Pricing Issues

5.2 Toxicity

5.3 Manufacturing

5.4 Resistance

6. Future Directions for CAR Cell Therapy

6.1 Allogeneic CAR Cell Therapies

6.2 Armored CARs

6.3 Dual Targeting CAR Cell Therapies

6.4 CAR Cell Therapy Combinations

6.5 CAR Natural Killer Cells

6.6 CAR Cell Therapies for Solid Tumors

7. Appendix

7.1 Primary Research

7.2 Sources

7.3 About the Authors

7.4 About GlobalData

7.5 Contact Us

7.6 Disclaimer

Frequently asked questions

Chimeric Antigen Receptor Cell Therapy thematic reports
Currency USD
$7,995

Can be used by individual purchaser only

$23,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Chimeric Antigen Receptor Cell Therapy was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Chimeric Antigen Receptor Cell Therapy in real time.

  • Access a live Chimeric Antigen Receptor Cell Therapy dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.